Company Profile
Unicycive Therapeutics Stock Price, News & Catalysts
- Ticker:
- UNCY
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.22 USD (-7.25%)
Close
Last updated: October 2, 2026
193M USD
Market cap
Why the stock is moving
Following the latest company update, “Unicycive Therapeutics Appoints Meredith Manning to Board of Directors”, UNCY closed down 3.09% at $4.55 on Oct 1, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Kidney Disease Therapeutics
Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease.
Oxylanthanum Carbonate
Oxylanthanum carbonate is an oral phosphate binder for hyperphosphatemia in dialysis patients. It is designed to achieve phosphate control with a lower pill burden than commonly used therapies.
Regulatory Resubmission Path
The FDA's prior review did not identify efficacy or safety deficiencies but required resolution of manufacturing-facility issues. A third-party vendor inspection is the key step preceding NDA resubmission.
Future catalysts
- Completion of the FDA inspection of the third-party oxylanthanum carbonate manufacturing facility.
- Resubmission of the oxylanthanum carbonate NDA following a successful facility inspection.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Unicycive Therapeutics (UNCY)?
Unicycive Therapeutics (UNCY) most recently closed at 4.22 USD, a -7.25% move versus the previous session.
What is the market cap of Unicycive Therapeutics (UNCY)?
Unicycive Therapeutics currently has a market capitalization of 193M USD on BioPharmSignal.
What does Unicycive Therapeutics do?
Kidney Disease Therapeutics Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease. Oxylanthanum Carbonate Oxylanthanum carbonate is an oral phosphate binder for hyperphosphatemia in dialysis patients. It is designed to achieve phosphate control with a lower pill burden than commonly used therapies. Regulatory...
On which exchange is UNCY stock listed?
Unicycive Therapeutics (UNCY) is associated with NASDAQ, United States, Biopharma.
What is Kidney?
Kidney Disease Therapeutics Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease.
Which conditions is Unicycive Therapeutics targeting with Kidney?
Kidney Disease Therapeutics Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease. Oxylanthanum Carbonate Oxylanthanum carbonate is an oral phosphate binder for hyperphosphatemia in dialysis patients. It is designed to achieve phosphate control with a lower pill burden than commonly used therapies. Regulatory...
How does Unicycive Therapeutics describe recent progress with Kidney?
Completion of the FDA inspection of the third-party oxylanthanum carbonate manufacturing facility. Resubmission of the oxylanthanum carbonate NDA following a successful facility inspection.
What is Disease?
Kidney Disease Therapeutics Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease.